Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Rani Therapeutics excels in 2022 with breakthrough drug delivery innovations

Rani Therapeutics made significant strides in 2022 with advancements in their RaniPill platform and promising Phase 1 results for RT-102, positioning the company for future growth.
Despite financial strength and successful partnerships, Rani faces challenges in maintaining clinical success rates, managing expenses, and navigating regulatory requirements.
Opportunities lie in expanding clinical trials, forging new partnerships, and innovating in drug delivery technologies to drive future growth and market expansion for Rani.

Rani Therapeutics excels in drug delivery innovation and clinical progress

Rani Therapeutics demonstrated strong performance in 2023 with positive Phase I results and successful oral delivery achievements, showcasing its innovative capabilities.
While facing challenges in negotiations and pipeline development, Rani has strengths in transformative technology and clinical expertise to navigate the competitive landscape.
With opportunities to expand drug delivery capabilities and strategic collaborations, Rani Therapeutics is poised for growth and advancement in the pharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 333,333 shares of Common Stock, together with Series C common warrants to purchase up to an aggregate of 3,333,333 shares of Common Stock, in a registered direct offering. Each share of Common Stock (or pre-funded warrant) is being sold together with one Series C common warrant at a combined purchase price of $3.00. The Series C common warrants will have an exercise price of $3.00 per share and will expire 5 years from the date of issuance.

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2.

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in September 2024. These conferences include:

Rani Therapeutics to Participate in September Investor Conferences

- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in August 2024. These conferences include:

Rani Therapeutics to Participate in August Investor Conferences

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics' Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 446,753 shares of Common Stock, together with Series A common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock and Series B common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock, in a registered direct offering. Each share of Common Stock and pre-funded warrant is being sold together with one Series A common warrant to purchase one share of Common Stock and one Series B common warrant to purchase one share of Common Stock at a combined purchase price of $3.08. The Series A common warrants and Series B common warrants will each have an exercise price of $3.08 per share, will each be exercisable 6 months from the date of issuance, and, in the case of Series A common warrants, will expire 18 months from the date of issuance, and in the case of Series B warrants, will expire five and a half years from the date of issuance.

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:

Rani Therapeutics to Participate in May Investor Conferences

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company's oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m.

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders.  The investigation seeks to determine whether Rani Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Rani Therapeutics's stock price.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 - - Initiation of Phase 2 clinical trial of RT-102, a RaniPill GO containing teriparatide for osteoporosis, expected by the year-end 2023 - - Announced RaniPill capsule was well-tolerated in 60-day, repeat oral-administration GLP safety study - - Announced successful drug delivery with RaniPill HC high-capacity capsule in multiple preclinical studies with cumulative >90% success rate - SAN JOSE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada.

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

RANI is developing a payload agnostic robotic pill (RaniPill) with enormous potential for penetration of several multi-billion injectable drug delivery markets. Pre-clinical and early-phase human studies consistently show effective and safe oral delivery of various molecules, including larger antibody-based biological therapies like adalimumab. Being an early-stage biotech, there are major risks, including fierce competition, challenged patents and low cash balance.

Rani Therapeutics: Excellent Technology But Major Risks Ahead

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar, CT-P43.

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that its abstract entitled “An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers the Human Parathyroid Hormone Analog hPTH (1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study,” presented on June 17 by Joshua Myers, Director of Clinical Operations at Rani, won the Presidential Poster Competition in the Bone and Mineral Metabolism category at the 105th annual meeting of The Endocrine Society (ENDO 2023). The Endocrine Society committee recognized Rani for its exceptional scientific work on RT-102, the company's oral robotic RaniPill® delivering teriparatide, or parathyroid hormone (PTH) (1-34), which is being developed as an oral osteoanabolic therapy for osteoporosis.

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that a late-breaking abstract “Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans” has been selected for poster presentation at the American Diabetes Association's (ADA) Scientific Sessions taking place on June 23 - 26, 2023 in San Diego, CA.

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

News for Rani Therapeutics Holdings Stock (RANI)